Adaptive Biotechnologies Q3 net income drops 71% to $2.81 million
ADPT•Adaptive Biotechnologies’ third-quarter 2026 net income fell 71% to $2.81 million and revenue declined 11% to $83.9 million. The company raised full-year MRD revenue guidance to $276 million–$286 million.
1. Quarterly results
Third-quarter 2026 revenue fell 11% to $83.9 million, while net income dropped 71% to $2.81 million. MRD revenue rose 28% to $72.6 million, and clonoSEQ test volume increased 46% to 39,587.
2. Guidance and testing
Adaptive Biotechnologies raised its full-year 2026 MRD revenue guidance to $276 million–$286 million and narrowed expected operating expenses to approximately $350 million. NCCN guidelines established a dedicated framework for MRD assessment in multiple myeloma, including annual testing during maintenance.
